2nd Circ. Told To Not Expand Antitrust Patent Fraud Standing
A pharmaceutical industry trade group has backed Bristol-Myers Squibb and its Celgene subsidiary in the Second Circuit, warning that health plans asking the appeals court to reinstate a proposed class action against...To view the full article, register now.
Already a subscriber? Click here to view full article